Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 4/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.67 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.56 |
| ▸ | TERT | O14746 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929014 | 0.87 | PTPN1 (0.66) | PTPN1DPP4MAPTABCG2GABRA3 | |
| SCHEMBL30559523 | 0.87 | PTPN1 (0.66) | PTPN1DPP4MAPTABCG2GABRA3 | |
| SCHEMBL633002 | 0.87 | PTPN1 (0.66) | PTPN1DPP4MAPTABCG2GABRA3 | |
| SCHEMBL633001 | 0.87 | PTPN1 (0.66) | PTPN1DPP4MAPTABCG2GABRA3 | |
| SCHEMBL22014223 | 0.86 | ABCG2 (0.59) | SNCAPTPN1MAPTABCG2GABRA3 | |
| SCHEMBL29929281 | 0.85 | PTPN1 (0.54) | SNCAPTPN1DPP4ABCG2GABRA3 | |
| SCHEMBL29929465 | 0.85 | PTPN1 (0.54) | SNCAPTPN1DPP4ABCG2GABRA3 | |
| SCHEMBL20608568 | 0.84 | NPC1 (0.58) | PTPN1MAPTABCG2GABRA3GABRA2 | |
| SCHEMBL28263080 | 0.83 | SNCA (0.71) | SNCAPTPN1DPP4PDE4APDE4B | |
| SCHEMBL24208085 | 0.83 | ABCG2 (0.56) | SNCAPTPN1DPP4ABCG2GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315957-A1 | COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASES, CONTAINING, AS ACTIVE INGREDIENT, GLYCYRRHIZA URALENSIS EXTRACT OR COMPOUND ISOLATED THEREFROM | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315957-A1 | COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASES, CONTAINING, AS ACTIVE INGREDIENT, GLYCYRRHIZA URALENSIS EXTRACT OR COMPOUND ISOLATED THEREFROM | PYGM, MUSK, GYS1 | SNCA 3345/4885PTPN1 2318/4885DPP4 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.